Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Allele Biotechnology & Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Allele Biotechnology & Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Allon Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Allon Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Allarity Therapeutics A/S Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Allarity Therapeutics A/S, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Algiax Pharmaceuticals GmbH Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Algiax Pharmaceuticals GmbH, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Akinion Pharmaceuticals AB Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Akinion Pharmaceuticals AB, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Akelos, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Akelos, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Albireo AB Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Albireo AB, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Alethia Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Alethia Biotherapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Amarillo Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Amarillo Biosciences, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
OrphAI Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of OrphAI Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Dominari Holdings, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Dominari Holdings, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
AIM ImmunoTech, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of AIM ImmunoTech, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.